Business Context and Reporting Period
This Form 8-K Current Report, filed on December 9, 2025, by Enliven Therapeutics, Inc. (ELVN), discloses significant changes in executive leadership and board composition. The report details the appointment of a new Chief Executive Officer (CEO) and the transition of the former CEO to a new operational role, effective December 11, 2025.
Key Financial Metrics and Compensation
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The financial data provided relates exclusively to executive compensation packages and equity grants:
- New CEO Base Salary: $660,000 annually.
- New CEO Target Bonus: 55% of base salary.
- New CEO Equity Grant: Option to purchase 875,000 shares of common stock.
- Former CEO (New Role) Base Salary: $500,000 annually.
- Former CEO (New Role) Target Bonus: 55% of base salary.
- Former CEO Equity Acceleration: 140,457 shares of outstanding stock options accelerated to vest.
Material Changes Versus Prior Period
The primary material change is the departure of Samuel Kintz as President, CEO, and Board member, replaced by Richard Fair in those roles. Samuel Kintz is transitioning to the role of Head of Pipeline. Additionally, the Board adopted the "2025 Inducement Equity Incentive Plan" to facilitate the equity grant to the new CEO without shareholder approval, reserving 875,000 shares for this purpose.
Guidance, Outlook, and Management Commentary
The filing does not provide financial guidance, revenue outlook, or specific operational milestones. Management commentary is limited to the strategic rationale for the leadership change, highlighting Richard Fair's 25+ years of experience in product development and commercialization, including 20 years with large pharmaceutical companies (Roche/Genentech and Johnson & Johnson) and a recent tenure as CEO of Bellicum Pharmaceuticals. The filing notes that Mr. Fair oversaw a $23 billion business at Roche/Genentech.
Risks and Contingencies: The filing outlines significant severance obligations for the new CEO in the event of a "Change in Control" or termination without cause, including potential lump-sum payments of 24 months' salary plus 150% of the target bonus, and full acceleration of unvested equity.
Important Facts for Investor Verification
- Verify the effective date of the leadership transition (December 11, 2025) and the immediate impact on the Board of Directors.
- Review the terms of the "2025 Inducement Equity Incentive Plan" to understand the dilution impact of the 875,000 share grant to the new CEO.
- Assess the financial implications of the severance agreements, specifically the potential liability for 24 months of salary and bonus acceleration in a change of control scenario.
- Confirm the forfeiture of Samuel Kintz's remaining unvested stock options in exchange for the acceleration of 140,457 shares.
- Note that this filing contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for liquidity and cash position details.